Loading
A phase 3 trial testing SG301 in multiple myeloma, now recruiting.
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06508983, led by Hangzhou Sumgen Biotech, and recruiting on the registry. Official title: A Phase 3 Randomised, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 360 participants (estimated). The study started in 2024-06-14 and primary completion is expected in 2027-03-31. No results have been posted on ClinicalTrials.gov.
Shares Hangzhou Sumgen Biotech, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.